5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris

1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications, Conference index, Lipodystrophy Workshop (IWADRW) 5th Paris 2003.

Articles included:

• Underlying mechanisms: adipocytes and cytokines
• More mitochondrial DNA depletion
• IMT and cardiovascular risk
• Reduced bone mineral density in HIV-positive women
• Rosiglitazone reversed peripheral lipoatrophy in HIV-patients with insulin resistance
• Additional benefits of exercise with metformin
• Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir
• Facial fat loss – measuring and treatment
• Uridine treatment for mitochondrial toxicity
• Breast enlargement in men and testosterone treatment
• Severe efavirenz psychotic events
• Treatment interruption can improve lipodystrophy

References:

Unless otherwise stated, all abstracts refer to the programme and abstracts from the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 8-11 July 2003, Paris and are published in Antiviral Therapy Volume 8 issue 4.

1. Capeau J, Caron M, Auclair M et al – Effects of NRTI on differentiation, response to insulin and apoptosis in cultured adipocytes. 2nd IAS Conference on HIV Pathogenesis and Treatment, 13–16 July, Paris. Abstract 206.
2. Yamauchi T – The roles and mechanisms of adipocytokines in insulin resistance. Abstract P3.
3. Khatami H, Mulligan K, Lo JC et al – Role of adipocytokines and body fat distribution in insulin resistance in HIV infection. Abstract 44
4. Frayn K – Adipose tissue and insulin resistance. Abstract P2.
5. Deveaud C, Beauvoit B, Rogoulet M – Effects of the treatment by nucleoside reverse transcriptase inhibitors on mitochondrial function of superficial and deep adipose tissues of rats. Abstract 50.
6. Maisonneuve C, Begriche K – Effects of AZT and d4T on ketone bodies and lipids in mice: possible role of beta-aminoisobutyric acid, a catabolite of thymine. Abstract 20.
7. Flint OP, Mulvey R, Elosua C et al – The effect of tenofovir, zidovudine and stavudine on adipocyte mitochondrial DNA, viability and lipid metabolism. Abstract 65.
8. Caron M, Auclair M, Kornprobst M et al – Effects of NRTI on differentiation, response to insulin and apoptosis in cultured adipocytes. Abstract 10.
9. Capeau J, Bastard JP, Cervera P et al – Increased IL-6 and TNF expression is related to increased apoptosis and decreased differentiation in adipose tissue from patients with HIV-related lipoatrophy. Abstract 9.
10. Nolan D, Hammond E, McKinnon E et al – Subcutaneous fat tissue mitochondrial DNA depletion and adipose toxicity are strongly associated with nucleoside reverse transcriptase inhibitor (NRTI) therapy in HIV-infected patients. Abstract 18.
11. Lopez S, Miro O, Martinez E et al – Does HIV infection itself have any effect on mitochondrial DNA content? Abstract 54.
12. Tebas P, Mondy K, De Ronde A et al – Effects of different antiretroviral treatments on mitochondrial DNA levels in PBMCs of HIV-infected patients. Abstract 60.
13. Shahmanesh M, Das S, Stolinski M et al – Effects of HIV infection, antiviral treatment and body fat changes on VLDL-apolipoprotein-B metabolism. Abstract 3.
14. Mercie P, Thiebaut R et al – Carotid intima-media thickness is moderately increased over time in HIV-1-infected patients. Abstract 2.
15. Hsue P, Lo J, Franklin A et al – Predictors of atherosclerosis and atherosclerotic progression in patients with HIV: the role of traditional and immunological risk factors. Abstract 35
16. Grinspoon S, Dolan SE, Huang JS et al – Reduced bone mineral density in HIV-infected women. Abstract 24.
17. Hadigan C, Yawetz S, Thomas A et al – A randomised, double-blind, placebo-controlled study of rosiglitazone for patients with HIV lipodystrophy. Abstract 12.
18. Oette M, Gobels K, Kurowski M et al – Rosiglitazone treatment of HIV-associated lipodystrophy syndrome: impact on the bioavailability of antiviral compounds. Abstract115.
19. Driscoll S, Meininger G, Lareau M et al – Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. Abstract 4.
20. Carr A, Martin A, Ringland C et al – Long term changes in lipodystrophy after switching from thymidine nucleoside analogues to abacavir. Abstract 16.
21. Raghavan S, Shlay JC et al – Rates of change in body composition among antiretroviral-naïve HIV-infected patients randomised to a didanosine/stavudine versus abacavir/lamivudine containing regimen in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) study (CPCRA 058). Abstract 13.
22. Frize G, Hughes A, Scullard G et al – Attitudes and perceptions of patients with facial lipoatrophy before and after intervention using polylactic acid. Abstract 110.
23. Guaraldi G, De Fazio D, Orlando G et al – Fat accumulation of the cheeks after autologous fat transfer for treating facial wasting in HIV-related lipodystrophy. Abstract 81.
24. Walker U, Koch E, Venhoff N et al – Uridine prevents and treats mtDNA depletion by NRTI pyrimidine analogues and fully restores mitochondrial function. Abstract 19.
25. Garcia M, Martinez E, Domingo P et al – Breast enlargement in male HIV-infected patients. Abstract 82.
26. Allin M, Reeves I, Everal I et al – Frequency of serious psychiatric adverse events with efavirenz. Abstract 129.
27. Trenado E – Lipodystrophic body changes and quality of life. Clinical management workshop.
28. Martinez E, Milenkovic A, Vidal S et al – Impact of structured treatment interruption on body composition of chronically infected patients: preliminary one year results. Abstract 88.